An observational study in Pancreatic Cyst and Pancreas Disease, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Stanford University · Observational
Among 54 studies in Pancreatic Cyst with a site in United States — 20 open to participants now, 23 under way, 1 of them phase 3. Pancreatic Cyst · United States.
Among the 54 studies in Pancreatic Cyst with a site in United States, this one is the 9th largest by planned enrollment of the 32 observational ones that give a count, is one of 4 that started in 2017, is one of 32 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 30th registered.
97 studies on the registry are indexed under Pancreatic Cyst; 37 are open to participants now.
Browse Pancreatic Cyst studies →20 of the 54 studies in Pancreatic Cyst with a site in United States are open now. Recruiting first, the newest first:
Orlando Health, Inc. · Sites in United States
Ages 18–100
Translational Genomics Research Institute · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Orlando Health, Inc. · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Pancreatic Cyst studies recruiting now, 25 (76%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 300 across 55 observational studies indexed under Pancreatic Cyst.
Median enrollment 53 across the 22 interventional studies, 300 across the 32 observational. Of the 26 that completed or were terminated, 5 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 54 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,170 studies on the registry; 433 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
Stanford University has 1 study filed under Pancreatic Cyst — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatic Cyst with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT06564571Orlando Health, Inc.Artificial Intelligence in Endoscopic Ultrasound | 2026-12 |
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Pancreatic Cyst with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bio-repository to collect bio-specimens from patients with 1) pancreatic cysts and 2) patients at high risk, defined by family history and/or genetic mutations, for pancreatic cancer.
Observational study to collect bio-specimens from 2 separate patient cohorts identified to be at high risk for subsequent development of pancreas cancer.
Patients at high risk for developing pancreas cancer defined by the presence of a pancreatic cyst and/or family history or genetic mutation for pancreas cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with pancreatic cyst undergoing endoscopic ultrasound and/or surgery who will have bio-specimens collected
Diagnostic Test: Bio-Specimen Collection
Patients with established family history and/or genetic mutations for Pancreas cancer who will have bio-specimens collected
Diagnostic Test: Bio-Specimen Collection
Collection of bio-specimens and observation over time.
Pancreas Cancer
Development of Pancreas Cancer
Time frame: 5-10 years
Plan to share: Undecided — De-identified clinical and demographic variables may be shared and linked to bio-specimens.
No publications or documents are linked to this record.
Started Sep 2017 (actual). Primary completion is estimated for Apr 2028, 127 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.